The National Institute of Diabetes & Digestive & Kidney Diseases

Manage a portfolio of clinical translation and clinical treatment grants for type 2 diabetes. 
Run the Type 1 Diabetes – Rapid Access to Intervention Development preclinical drug development program. 

Program official for the TINSAL-T2D study, an efficacy study of salsalate in

      type 2 diabetes. 

Participate in other large, NIDDK clinical studies including HEALTHY and Longitudinal

      Assessment of Bariatric Surgery. 

Lead the Clinical Team within DEM

B.S. in Nutrition, Summa Cum Laude, Texas Christian University, Fort Worth, TX

      (1968‑1972)

M.D., Graduation with High Honors, University of Texas Medical Branch,

      Galveston, TX (1976‑1979)

Internship and Residency in Medicine, University of California at Irvine Medical Center,

      Orange, CA (1979-1982)

Fellowship in Endocrinology and Metabolism, Washington University School

      of Medicine, St. Louis, MO (1982-1985)

Instructor, Assistant Professor, Department of Internal Medicine, Washington University

      School of Medicine (1985-1989)

Various clinical research positions with major pharmaceutical companies (1989-1999)

      including Amgen, Bristol-Myers Squibb and Hoffman-LaRoche

Vice President-CV/Endocrine/Metabolic Diseases Clinical Research, Pharmacia,

      Peapack, NJ (1999-2003)

Board certified in Internal Medicine and Endocrinology and Metabolism

NIDDK Bench to Bedside Translation Working Group (Chair)

The Biomarkers Consortium for the Foundation for the National Institutes of Health

      (co-chair)

NIDDK representative the NIH pilot RAID program (lead a subcommittee on IC

      Coordination and Outreach and participate in the NIH-RAID Evaluation and Planning

      Subcommittee)

Type 2 diabetes planning group (Chair)

NIDDK Obesity Working Group

NIDDK Diabetes Complications Working Group

ADA Insulin Standardization Working Group